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Background-—Mineralocorticoid receptor (MR) antagonists have protective effects in the brain during experimental ischemic
stroke, and we have previously demonstrated a key role for myeloid MR during stroke pathogenesis. In this study, we explore both
model- and sex-specific actions of myeloid MR during ischemic stroke.
Methods and Results-—The MR antagonist eplerenone significantly reduced the infarct size in male (control, 99.5 mm3; eplerenone,
74.2 mm3; n=8 to 12 per group) but not female (control, 84.0 mm3; eplerenone, 83.7 mm3; n=6 to 7 per group) mice after transient
(90-minute) middle cerebral artery occlusion. In contrast to MR antagonism, genetic ablation of myeloid MR in female mice
significantly reduced infarct size (myeloid MR knockout, 9.4 mm3 [5.4 to 36.6]; control, 66.0 mm3 [50.0 to 81.4]; n=6 per group) after
transient middle cerebral artery occlusion. This was accompanied by reductions in inflammatory gene expression and improvement
in neurological function. In contrast to ischemia-reperfusion, myeloid MR–knockout mice were not protected from permanent middle
cerebral artery occlusion. The infarct size and inflammatory response after permanent occlusion showed no evidence of protection
by myeloid MR knockout in photothrombotic and intraluminal filament models of permanent occlusion.
Conclusions-—These studies demonstrate that MR antagonism is protective in male but not female mice during transient middle
cerebral artery occlusion, whereas genetic ablation of myeloid MR is protective in both male and female mice. They also highlight
important mechanistic differences in the role of myeloid cells in different models of stroke and confirm that specific myeloid
phenotypes play key roles in stroke protection. ( J Am Heart Assoc. 2012;1:e002584 doi: 10.1161/JAHA.112.002584)
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M ineralocorticoid receptor (MR) activation is a contrib-uting factor in the pathophysiology of a wide range of
diseases. Elevated levels of aldosterone, a physiological MR
activator, are known to induce hypertension, alter inflamma-
tion and fibrosis, and exacerbate cardiovascular diseases.
Clinical, therapeutic interventions for the treatment of hyper-
tension, heart failure, and post–myocardial infarction remod-
eling have successfully used MR antagonists.1,2 However, the
benefit of this class of drugs could extend to the treatment of
other cardiovascular diseases, like ischemic stroke. In fact,
the MR antagonists eplerenone and spironolactone both are
markedly effective in reducing infarct size and neurological
deficit after ischemic stroke in male rats and mice.3–5
Despite the known protective effects of MR antagonists, the
exact mechanisms of protection are not well understood. In
addition to demonstrating a remarkable efficacy of MR antago-
nists to decrease risk of death during heart failure, the
Randomized Aldactone Evaluation Study (RALES) study also
showed that these effects occur without altering blood pressure.2
Furthermore, spironolactone and eplerenone protected rodents
from stroke injury without affecting blood pressure.3,5 However,
new information recently has come to light as a result of cell-
specific genetic ablation techniques that allow for localization of
MR activity key to the pathophysiology of disease.
We have previously identified MR as a regulator of
macrophage activation and demonstrated that MR antagonists
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or myeloid MR knockout (MyMRKO) induces an alternatively
activated macrophage (AAM) phenotype.6 Conversely, MR
activation by aldosterone enhances a proinflammatory, clas-
sically activated macrophage (CAM) phenotype. Macrophage
phenotypes influence the outcome in cardiac remodeling after
infarct,7,8 and deletion of MR from myeloid cells reduced
cardiac remodeling due to NG-nitro-L-arginine methyl ester/
angiotensin II.6 These studies demonstrated that MR activa-
tion in myeloid cells plays a key role in the promotion of
pathophysiological cardiac remodeling.
The neuroprotective effects of MR antagonists have become
the focus of many recent studies, and it is now known that MR
activation in myeloid cells plays an important role during
ischemic stroke. MyMRKO mice are protected from ischemia-
reperfusion injury in the brain, which demonstrates the
importance of myeloid cells as targets for MR antagonists
during ischemic stroke.9 Previous studies also indicated that
female rats lack responsiveness to MR antagonists10; there-
fore, we tested whether genetic myeloid MR ablation was
protective in females during ischemic stroke. To further
evaluate and characterize this neuroprotective phenotype, we
also tested whether MyMRKO mice were protected in models
of permanent middle cerebral artery (MCA) occlusion.
Methods
Mice
All animal procedures were performed in accordance with the
Guide for the Care and Use of Laboratory Animals (NIH
Publication No. 80-23) and were approved by the University
Committee on Use and Care of Animals of the University of
Michigan. Adult male and female mice weighing between 25 and
30 g were used. MyMRKO mice (MRflox/flox; LysMCre+/) and
littermate controls (MRflox/flox) on a C57BL/6 background were
generated as described previously.6 Wild-type C57BL/6J mice
were purchased from The Jackson Laboratory (Bar Harbor, ME,
USA), and MyMRKO and FC mice were bred in-house. Mice
were maintained on standard laboratory chow (5001, LabDiet)
and water ad libitum. Mice were administered eplerenone
(Sandoz, Princeton, NJ) (160 mg/kg per day) in rodent chow
(Harlan Teklad, TD.10030) for 1 week before experiments.
Intraluminal Filament MCA Occlusion
MCA occlusion by the intraluminal filament method was
performed as previously described.11 The mice were anesthe-
tized with 1% to 3% isoflurane, and a 6-0 silicon rubber–coated
nylon monofilament (Docoll Corporation, CA) was inserted into
the right internal carotid artery. Regional cerebral blood flow
was monitored by laser Doppler flowmetry (Transonic BLF21)
before and during monofilament insertion to verify MCA
occlusion. Occlusion was defined as a reduction in cerebral
blood flow to a level <20% of baseline. For ischemia-
reperfusion studies, the suture was removed after 90 minutes,
and animals were euthanized 24 hours after suture removal.
For permanent occlusion experiments, the suture remained
tied in place until the animals were euthanized.
Photothrombotic Permanent MCA Occlusion
For induction of photothrombotic stroke, the temporalis
muscle was transected, and the left MCA was exposed by
drilling a 1-mm burr hole through the skull. A laser Doppler
flow probe (Type N [18 Ga], Transonic Systems) was placed
distal to the exposed MCA to monitor cerebral blood flow. A
3.5-mW green light laser (540 nm, Melles Griot) was directed
at the MCA, and Rose Bengal stain (Acros Organics) was
injected intravenously (50 mg/kg). The relative tissue perfu-
sion units of the cerebral cortex were monitored continuously
with a laser Doppler flowmeter (Transonic BLF21). Stable
occlusion was defined as a drop in tissue perfusion units to a
level <20% of baseline for >10 minutes.
Measurement of Infarct Volume
All infarcts were analyzed with magnetic resonance imaging
(MRI). At 24 and 72 hours after transient or permanent MCA
occlusion, mice were anesthetized with 2% isoflurane/air
mixture throughout MRI examination. Mice lay prone, head first
in a 7.0T Varian Unity Inova MR scanner (183-mm horizontal
bore; Varian, Palo Alto, CA), with the body temperature
maintained at 37°C by forced heated air. A double-tuned volume
radiofrequency coil was used to scan the head region of the
mice. Axial T2-weighted images were acquired through the use
of a fast spin-echo sequence with the following parameters:
repetition time/effective echo time, 4000/60ms; echo spacing,
15 ms; number of echoes, 8; field of view, 20920 mm; matrix,
2569128; slice thickness, 0.5 mm; number of slices, 25; and
number of scans, 1 (total scan time 2.5 minutes). The infarct
volumes were analyzed in NIH ImageJ software (version 1.43) by
a blinded observer, and infarct volumes were corrected to
account for brain swelling.12,13 The following equation was used
to calculate the corrected T2-lesion volumes:
Corrected T2 lesion volume ¼ TV ððCVþ ðIV LVÞÞ
 ððTV/2)/CVÞÞ
TV indicates total volume in both hemispheres; CV, contra-
lateral volume; IV, ipsilateral volume; and LV, lesion volume.
Evaluation of Neurological Deficit
Neurological deficits were determined 24 hours after MCA
occlusion. Neurological scores were assigned on the basis of
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the following criteria: 0, no deficit; 1, forelimb flexion and
torso turning to the contralateral side when held by tail; 2,
circling to contralateral side; 3, unable to bear weight on
contralateral side; and 4, no spontaneous locomotor activity.
Gene Expression Analysis
mRNA expression was measured with quantitative reverse
transcription–polymerase chain reaction. Total RNA was
extracted from frozen whole cerebral hemispheres through
the use of TRIzol reagent and then was purified with the
RNeasy Mini Kit (Qiagen). Purified RNA (1 lg) was reverse
transcribed to cDNA with an Applied Biosystems kit. Quan-
titative reverse transcription–polymerase chain reaction was
performed with a Bio-Rad iCycler. The relative mRNA expres-
sion was quantified by the comparative method, and mRNA
was normalized to b-actin.
Immunohistochemistry
Mice were euthanized and transcardially perfused with
heparinized saline (1 U/mL) and then 4% paraformaldehyde.
The brains were removed and postfixed in 4% paraformalde-
hyde for 1 week. The cerebrum then was cut into 2-mm-thick
serial coronal sections. Sections were embedded in paraffin,
cut into 10-lm sections, and mounted on a slide. Iba1+
microglia and macrophages were detected through the use of
goat polyclonal anti-Iba1antibody (Abcam, ab5076, Cam-
bridge, MA, USA) at a 1:300 dilution on paraffin-embedded
sections. Immunoreactivity was visualized with an ABC kit
(Vector Labs, Burlingame, CA, USA) through the use of a
biotinlyated rabbit anti-goat secondary antibody and diami-
nobenzadine. Iba1+ cells were quantified and expressed as
number of cells per field (409 objective). Two 409 fields
were counted by a blinded observer in each anatomic region
and were averaged to obtain the number of Iba1+ microglia
and macrophages.
Statistics
A Kolmogorov-Smirnov test and normal quantile plots were used
to determine if data were normally distributed. For normally
distributed data, statistical comparison of mean values between
groups was performed with the Student t test, and values are
presented as mean with standard error of the mean. Data that
were not normally distributed were analyzed with the nonpara-
metric Mann-Whitney test and are presented as median with
interquartile range. All statistical analysis of data was performed
in GraphPad Prism (version 5; GraphPad Software, Inc). P<0.05
was considered significant. A limitation of the present study is its
restricted ability to detect small differences between groups
because of low statistical power.
Results
Female MyMRKO Mice Are Protected From
Transient MCA Occlusion
Previous studies indicated that MR antagonists are protective
in male but not female stroke-prone spontaneously hyperten-
sive rats during ischemic stroke.10 Similarly, we found that
female mice also lack responsiveness to the MR antagonist
eplerenone during 90-minute transient MCA occlusion fol-
lowed by 24 hours of reperfusion. Pretreatment with eplere-
none reduced the infarct size in male mice (control, 99.5
mm3; eplerenone, 74.2 mm3). In female mice, the eplerenone-
treated group showed no important decrease in infarct size
(control, 84.0 mm3; eplerenone, 83.7 mm3) (Figure 1A and
1B). Male MyMRKO mice are highly protected during ische-
mia-reperfusion in the brain.9 To determine whether a sexual
dimorphic effect also exists in genetically ablated MyMRKO
mice, we subjected female mice to transient MCA occlusion.
We performed a 90-minute transient MCA occlusion followed
by 24 hours of reperfusion, and the infarcts were assessed by
T2-weighted MRI. Analysis of MRI scans showed a dramatic
reduction in infarct size in female MyMRKO mice (Figure 2A).
Figure 1. MR antagonism with eplerenone is protective in male but
not female mice during transient MCA occlusion. Representative MRI
sections and infarct volumes from control and eplerenone-treated (A)
male and (B) female mice 24 h after transient (90-minute) MCA
occlusion. Data are expressed as mean with standard error of the
mean. n=6 to 12 per group.
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This is consistent with what we have observed in male mice.
Quantification of infarct sizes in ImageJ software revealed a
dramatic reduction in infarct size in the ischemic hemisphere
of MyMRKO compared to floxed controls (FC) (Figure 2B). The
median (interquartile range) was 66.0 mm3 (50.0 to 81.4) in
the FC group and 9.4 mm3 (5.4 to 36.6) in the MyMRKO group
(P=0.004) (Figure 2C). The reduction in infarct size in
MyMRKO mice was accompanied by an improvement in
neurological function, indicated by lower neurological scores
(median [interquartile range]: FC, 2.0 [1.0 to 2.3]; MyMRKO,
0.5 [0 to 1.0]; P=0.01) (Figure 2D).
Female MyMRKO Mice Have a Suppressed
Inflammatory Response
Because MR is a regulator of macrophage polarization, we
analyzed the mRNA expression of genes induced in CAM and
AAM phenotypes by using quantitative reverse transcription–
polymerase chain reaction. Female MyMRKO mice exposed to
transient MCA occlusion exhibited a dramatic suppression in
inflammatory gene expression compared to similarly treated
FC female mice. The expression of proinflammatory CAM
genes (IL-1b, TNF-a, MCP1, and MIP1a) was suppressed in
ischemic hemispheres of MyMRKO mice as compared with FC
mice (Figure 3A). We also examined a panel of genes (Arg1,
Ym1, IL1RA, and F13a1) expressed by AAMs. The expression
of Arg1 and YM1 was suppressed in MyMRKO mice
(Figure 3B). No statistically significant differences in IL1RA
and F13a1 were detected between MyMRKO and FC mice, but
their average levels of expression were lower, and this study
is limited by low power.
Figure 2. Infarct size and neurological deficit in female MyMRKO
mice after transient MCA occlusion. A, Representative MRI sections
from FC and MyMRKO mice 24 h after transient (90-minute) MCA
occlusion. Infarct sizes in FC and MyMRKO mice represented as (B)
fraction in ipsilateral hemisphere and (C) total infarct volume.
D, Functional outcome was assessed by scoring neurological deficit
in mice after 24 h. Data are expressed as median with interquartile
range. n=6 per group.
Figure 3. Female MyMRKO mice have suppressed inflammatory gene expression after transient MCA occlusion. Gene expression of (A)
proinflammatory CAM markers and (B) AAM markers 24 h after transient (90-minute) MCA occlusion. All genes were normalized to b-actin.
*P<0.05, **P<0.01. Data are expressed as mean with standard error of the mean. n=6 per group. Contra indicates contralateral; Ipsi, ipsilateral.
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MyMRKO Mice Are Not Protected During
Permanent MCA Occlusion
MR antagonists have been shown to provide neuroprotection
during both transient and permanent occlusion models of
ischemic stroke. To evaluate the role of MyMRKO in conditions
of permanent occlusion, we subjectedMyMRKO and FCmice to
MCA photothrombosis. Infarct sizes were assessed by MRI 24
hours after MCA photothrombosis. Surprisingly, no important
differences in infarct volumes were observed between
MyMRKO and controls among both male and female mice
(Figure 4). Because a reduction in perfusion during permanent
occlusion reduces infiltration of circulating inflammatory cells,
we also assessed the infarcts at 72 hours, when more
peripheral immune cells are recruited.14 Larger infarct volumes
were observed at 72 hours because of infarct expansion, but
there continued to be no protection by MyMRKO.
We had previously observed a reduction in the number of
Iba1+ cells (microglia and macrophages) in the infarct core in
MyMRKO mice during transient occlusion.9 Therefore, we
examined whether there were changes in microglia and
macrophage numbers during permanent MCA photothrombo-
sis. Increases in Iba1+ microglia and macrophages were
present in the ipsilateral hemisphere of both MyMRKO and FC
mice, but no differences were detected between MyMRKO
and FC mice (Figure 5). Similarly, no baseline differences
were observed in the contralateral hemispheres. To further
evaluate the changes in the inflammatory response, we
analyzed the CAM and AAM markers. The gene expression of
CAM markers (IL-1b, TNF-a, MCP1, and MIP1a) were all
Figure 4. Infarct size in MyMRKO mice after permanent, photo-
thrombotic MCA occlusion. A, Representative MRI sections from
male MyMRKO mice 24 h after MCA photothrombosis. Infarct sizes
in (B) male and (C) female FC and MyMRKO mice represented as
fraction in ipsilateral hemisphere and total infarct volume. Data are
expressed as median with interquartile range. n=5 to 6 per group.
Figure 5. Immunohistochemical analysis of macrophages and microglia 24 h after photothrombotic MCA occlusion. A, Representative
photomicrographs of contralateral and ipsilateral hemispheres from FC and MyMRKO mice stained with microglia- and macrophage-
immunoreactive Iba1 antibody. B, Quantification of Iba1 immunoreactive cells in the infarct core. Data are expressed as median with interquartile
range. n=5 per group.
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significantly increased in the ipsilateral hemisphere of
MyMRKO and FC mice compared to the contralateral
hemisphere, but no changes between groups were observed
(Figure 6A). Similarly, no significant differences were detected
in AAM markers between MyMRKO and FC mice (Figure 6B).
MR antagonists have not been tested in the photothrom-
bosis stroke model, and it is unknown whether they are
protective in this model. Therefore, we also tested the effect
of MyMRKO during permanent MCA occlusion by using the
intraluminal filament model, in which the MR antagonists are
known to be effective at reducing infarct size.3 Consistent
with the results from MCA photothrombosis, we found no
protection by MyMRKO with regard to infarct size or
neurological deficit 24 hours after permanent MCA occlusion
with the intraluminal filament model (Figure 7). These data
indicate that reperfusion is necessary for myeloid cell
phenotypes to alter stroke outcome.
Discussion
In the present study, we evaluated the role of myeloid MR in
female mice and in multiple models of ischemic stroke. We
found that male but not female mice were protected from
cerebral ischemia by pretreatment with the MR antagonist
eplerenone. In contrast to MR antagonism, genetic ablation of
MR in myeloid cells is neuroprotective in female mice. Like
males, female MyMRKO mice were dramatically protected
from transient occlusion and had dramatic reductions in
infarct size, neurological deficit, and inflammatory response.
Furthermore, we also show that the neuroprotective pheno-
type in MyMRKO mice exists during transient MCA occlusion
but not during permanent MCA occlusion. MyMRKO mice
displayed no differences in infarct size and inflammation in
Figure 6. Expression of inflammatory markers in FC and MyMRKO mice 24 h after photothrombotic MCA occlusion. Gene expression of (A)
proinflammatory CAM markers and (B) AAM markers 24 h after MCA photothrombosis. All genes were normalized to b-actin. Data are expressed
as mean with standard error of the mean. n=6 per group. Contra indicates contralateral; Ipsi, ipsilateral.
Figure 7. Infarct size in MyMRKO mice after permanent MCA
occlusion with the intraluminal filament model. A, Representative
MRI sections from male FC and MyMRKO mice 24 h after permanent
MCA occlusion. Infarct sizes in FC and MyMRKO mice represented as
(B) fraction in ipsilateral hemisphere and (C) total infarct volume.
D, Functional outcome was assessed by scoring neurological deficit
in mice after 24 h. Data are expressed as median with interquartile
range. n=5 per group.
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MCA photothrombosis and intraluminal filament models of
permanent occlusion.
It has been well established that MR antagonists have
protective effects and reduce stroke lesion volumes in male
mice and stroke-prone spontaneously hypertensive rats. The
majority of experimental cardiovascular studies in animal
models only report the use of male animals. The Stroke
Therapy Academic Industry Roundtable (STAIR) recommenda-
tions for performing preclinical stroke studies include the use
of multiple models (permanent and transient occlusion) in both
male and female subjects to better assess the viability of drugs
for clinical translation.15 In accordance, we investigated the
effects of the MR antagonist eplerenone during transient MCA
occlusion in both sexes and discovered that it is protective in
male but not female mice. Although the statistical power in this
study was low, we detected no indication of protection in
eplerenone-treated female mice. This is consistent with a
previous report published by Rigsby and colleagues10 demon-
strating that neuroprotection by MR antagonists does not
extend to female rats. They found that nonovarectomized and
ovarectomized female rats lacked responsiveness to both
spironolactone and eplerenone during ischemic stroke. Female
stroke-prone spontaneously hypertensive rats also were
shown to have elevated levels of MR in the cerebral vasculature
as compared to males, but it is not known whether this
contributes to the sexual dimorphism of MR antagonists.
MR antagonists also have been shown to display sexual
dimorphism in their ability to reduce blood pressure. In a salt-
induced hypertension model, the MR antagonist spironolac-
tone was effective in reducing blood pressure in male but not
female Wistar rats.16 Similarly, intracerebroventricular injec-
tion of the MR antagonist RU28318 resulted in a reduced
antihypertensive response in female rats compared to
males.17,18 Despite the differences in the likely mechanism
of blood pressure lowering in these 2 models, females lacked
responsiveness to MR blockade. The sexual dimorphic effects
of MR antagonists have been suggested to be due to
alternative drug metabolism in females, and it has been
shown that the MR antagonist eplerenone is differentially
metabolized in male and female mice. Interestingly, though,
male rats have been shown to metabolize eplerenone more
rapidly than females, making this explanation unlikely.19
Furthermore, this hypothesis is confounded by the observa-
tion that MR antagonists have beneficial effects in females
during models of cardiac remodeling and cerebral aneurysm
formation.20–22 Taken together, the available data suggest
that the sexual dimorphic actions might be due to model-
specific effects rather than differential drug metabolism.
In contrast to MR antagonism, our studies show that
genetic ablation of myeloid MR is protective in both male and
female mice after transient MCA occlusion. MyMRKO reduced
infarct volume and suppressed inflammation while improving
neurological function. These results indicate that there could
be differential sexual dimorphism of MR antagonists in
different cell types. In fact, MR clearly has effects in other
cell types within the brain and cerebrovasculature, and MR
overexpression in neurons actually has been shown to have
beneficial effects during cerebral ischemia.23 It is possible,
then, that sex-dependent differences in the expression and
regulation of neuronal MR or in the intracellular metabolism of
MR agonists or antagonists could play a role in sexually
dimorphic responses to MR antagonists in stroke. The studies
by Rahmouni and colleagues17 in which intracerebroventric-
ular injections of MR antagonists exhibited reduced efficacy in
females might indeed indicate that sexual dimorphism of MR
antagonists exists in nonmyeloid cell types in the brain. In
light of these data, our studies indicate that myeloid-targeted
drug delivery could be an effective strategy in the treatment of
stroke. Modification of drugs to reduce passage across the
blood–brain barrier could provide a means to target circulat-
ing cells without affecting other cell types in the brain.
MR antagonists are protective in both transient and
permanent MCA occlusion. In contrast, MyMRKO mice were
protected during transient MCA occlusion but not during
models of permanent MCA occlusion. There were no impor-
tant differences detected in infarct size, macrophage/micro-
glia recruitment, and inflammatory gene expression between
MyMRKO and controls subjected to photothrombotic stroke.
Similarly, no important differences in infarct size or neuro-
logical deficit were observed during permanent occlusion with
the intraluminal filament model. Our finding that MyMRKO is
protective in transient but not permanent occlusion could
provide important insight into the mechanism of protection
with myeloid-specific MR ablation and the role that myeloid
MR plays in the pathophysiology of stroke. Several studies
targeting inflammatory molecules (neutrophil elastase,
CD11b/CD18, matrix metalloproteinases, intercellular adhe-
sion molecule 1) also have shown protective effects in
transient but not permanent occlusion.24–28 Our present
experiments support the hypothesis that inflammatory cells
are a key component of the response to reperfusion injury and
also demonstrate a key role for the MR and the macrophage
lineage in this process.
In permanent occlusion models of stroke, cerebral blood
flow is not restored, and there is reduced and delayed
inflammatory cell infiltration from the peripheral circulation.
The supply of infiltrating cells from the periphery is dependent
on the extent collateral vasculature. Thus, much of the early
inflammatory cell recruitment during permanent occlusion is
due to resident immune cells within the brain parenchyma.
This might suggest that neuroprotection in MyMRKO mice
during transient occlusion is a result of modulating the
trafficking of circulating myeloid immune cells rather than
altering the activation phenotypes of microglia or macrophag-
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es within the brain parenchyma. However, temporal changes
in macrophage activation states after ischemic stroke are
largely unknown, and alterations in the balance of CAM and
AAM phenotypes could be a crucial factor in altering stroke
severity. Female MyMRKO mice exhibited suppression of both
CAM and AAM markers 24 hours after transient ischemia, but
it will be important to examine the phenotypic changes in
activation states at earlier time points. Suppression of some
AAM markers was greater in females than in males (described
previously) and could reflect previously observed sexually
dimorphic Th1/Th2 immune responses.29–32 Because myeloid
cells are important in reperfusion injury and oxidative damage,
a reduction in inflammatory cell recruitment or decrease in
CAM phenotypes also could reduce reperfusion injury.
In conclusion, we demonstrate that genetic ablation of
myeloid MR, but not MR antagonism, is protective during
transient occlusion in female mice. Our results further
delineate the actions of myeloid MR during ischemic stroke
and indicate that myeloid MR plays a more important role in
reperfusion injury. Thus, MR-targeted drug development might
be a feasible therapeutic intervention for stroke, particularly
when combined with reperfusion strategies.
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